BIIB014 Phase 2a Monotherapy
NCT00451815 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2023-08-23
Summary
To assess the preliminary safety and tolerability of multiple oral doses of BIIB014 in subjects with early PD.
Conditions
Interventions
- DRUG
-
active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Biogen Idec · Biogen
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Model
- PARALLEL
Eligibility
- Min Age
- 30 Years
- Max Age
- 78 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
NCT05348785 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
NCT06602193 ·Status: RECRUITING ·Phase: PHASE2
-
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
NCT07005180 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
NCT05418673 ·Status: TERMINATED ·Phase: PHASE3
-
Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067
NCT02071810 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate SYN115 in Parkinson's Disease
NCT00605553 ·Status: COMPLETED ·Phase: PHASE2
-
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
NCT02157714 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease
NCT02006290 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease
NCT02224664 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease
NCT06175767 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)
NCT04875962 ·Status: COMPLETED ·Phase: PHASE1
-
A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
NCT04658186 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067
NCT01568034 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
NCT04777331 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease.
NCT05924243 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202
NCT02763787 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202
NCT02763800 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
NCT06309147 ·Status: RECRUITING ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease
NCT03257046 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
NCT02565628 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of DA-9805 for Parkinson's Disease
NCT03189563 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
NCT06976268 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period Dyskinesias
NCT01172379 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease
NCT04127695 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline
NCT01879748 ·Status: COMPLETED ·Phase: PHASE1